DSM's XD Tech boosts yields five-10-fold
Dutch life sciences company DSM says that its proprietary XD Technology boosts bioreactor productivity and titers of mammalian cell culture processes by five to10-fold for the production of proteins and antibodies.
Recent studies completed at the R&D labs of DSM Biologics in Groningen, the Netherlands, demonstrated that the yields from CHO-based cell cultures can be increased five to10-fold over their previous fed-batch processes using only off the shelf, commercially-available media. The XD Technology has been tested for antibody and recombinant protein production across multiple cell lines, and the increase was realized in all cases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze